Extracellular Trypanosoma cruzi calreticulin in the host-parasite interplay

Trends in Parasitology

Volumn 27, Issue 3, 2011, Pages 115-122

  Ramírez, Galia ^a   Valck, Carolina ^a   Ferreira, Viviana P ^b   López, Nandy ^a   Ferreira, Arturo ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C4; DECAY ACCELERATING FACTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHAGAS DISEASE; CHEMOTAXIS; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; EVOLUTIONARY ADAPTATION; HOST PARASITE INTERACTION; HUMAN; IMMUNOGENICITY; MORPHOGENESIS; NONHUMAN; PARASITEMIA; PROTEIN PROTEIN INTERACTION; REVIEW; TRYPANOSOMA CRUZI; TUMOR GROWTH; UMBILICAL CORD BLOOD;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CALRETICULIN; HOST-PARASITE INTERACTIONS; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI; VERTEBRATA;

EID: 79952102948     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.12.007     Document Type: Review

References (78)

1. Rodrigues J., Albajar P. Chagas disease: a new worldwide challenge. Nature 2010, 465:S6-S7.
2. Clayton J. Chagas disease 101. Nature 2010, 465:S4-S5.
3. Clayton J. Chagas disease: pushing through the pipeline. Nature 2010, 465:S12-S15.
4. Norris K.A., et al. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J. Immunol. 1991, 147:2240-2247.
5. Norris K.A., Schrimpf J.E. Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi. Infect. Immun. 1994, 62:236-243.
6. Meri S., Pangburn M.K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3982-3986.
7. Tomlinson S., Raper J. Natural Human Immunity to Trypanosomes. Parasitol. Today 1998, 14:354-359.
8. Ferreira V., et al. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol. 2004, 172:3042-3050.
9. López N.C., et al. Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin. PLoS Negl. Trop. Dis. 2010, 4:e730.
10. Jaworski D.C., et al. Presence of calreticulin in vector fleas (Siphonaptera). J. Med. Entomol. 1996, 33:482-489.
11. Kasper G., et al. A calreticulin-like molecule from the human hookworm Necator americanus interacts with C1q and the cytoplasmic signalling domains of some integrins. Parasite Immunol. 2001, 23:141-152.
12. Labriola C., et al. Trypanosoma cruzi calreticulin is a lectin that binds monoglucosylated oligosaccharides but not protein moieties of glycoproteins. Mol. Biol. Cell 1999, 10:1381-1394.
13. Conte I., et al. The interplay between folding-facilitating mechanisms in Trypanosoma cruzi endoplasmic reticulum. Mol. Biol. Cell 2003, 14:3529-3540.
14. Ribeiro C.H., et al. Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity. Mol. Immunol. 2009, 46:1092-1099.
15. Souto-Padron T., et al. Immunocytochemical localisation of calreticulin in Trypanosoma cruzi. Histochem. Cell Biol. 2004, 122:563-569.
16. Stuart G.R., et al. The C1q and collectin binding site within C1q receptor (cell surface calreticulin). Immunopharmacology 1997, 38:73-80.
17. Stuart G.R., et al. Localisation of the C1q binding site within C1q receptor/calreticulin. FEBS Lett. 1996, 397:245-249.
18. Ferreira V., et al. Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis?. Trends Parasitol. 2005, 21:169-174.
19. Ferreira V., et al. Role of calreticulin from parasites in its interaction with vertebrate hosts. Mol. Immunol. 2004, 40:1279-1291.
20. Valck C., et al. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol. Immunol. 2010, 47:1516-1521.
21. Gal P., et al. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol. Immunol. 2009, 46:2745-2752.
22. Wallis R., et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 2010, 215:1-11.
23. Araya J.E., et al. Calcineurin B of the human protozoan parasite Trypanosoma cruzi is involved in cell invasion. Microbes Infect. 2008, 10:892-900.
24. Yoshida N., Cortez M. Trypanosoma cruzi: parasite and host cell signaling during the invasion process. Subcell. Biochem. 2008, 47:82-91.
25. Rimoldi M.T., et al. Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes. J. Clin. Invest. 1989, 84:1982-1989.
26. Ramirez G., et al. Trypanosoma cruzi calreticulin: A novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiology 2010, 216:265-273.
27. Obeid M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
28. Aguilar L., et al. F(ab')2 antibody fragments against Trypanosoma cruzi calreticulin inhibit its interaction with the first component of human complement. Biol. Res. 2005, 38:187-195.
29. Marcelain K., et al. Development of an immunoenzymatic assay for the detection of human antibodies against Trypanosoma cruzi calreticulin, an immunodominant antigen. Acta Trop. 2000, 75:291-300.
30. Burton D.R., Woof J.M. Human antibody effector function. Adv. Immunol. 1992, 51:1-84.
31. Xu Y., et al. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 1994, 269:3469-3474.
32. Garg N., Tarleton R.L. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect. Immun. 2002, 70:5547-5555.
33. Yao L., et al. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J. Leukoc. Biol. 2002, 71:47-53.
34. Pike S.E., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 1998, 188:2349-2356.
35. Pike S.E., et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999, 94:2461-2468.
36. Cai K.X., et al. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin. Cancer Res. 2008, 14:939-949.
37. Jazowiecka-Rakus J., et al. Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim. Pol. 2007, 54:125-133.
38. Yao L., et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol. Immunother. 2002, 51:358-366.
39. Kallinikova V.D., et al. Anticancer properties of flagellate protozoan Trypanosoma cruzi Chagas, 1909. Izv. Akad. Nauk Ser. Biol. 2001, 299-311.
40. Oliveira E.C., et al. Chronic Trypanosoma cruzi infection associated with low incidence of 1,2-dimethylhydrazine-induced colon cancer in rats. Carcinogenesis 2001, 22:737-740.
41. Ishii J., et al. SREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREC-I through its extracellular domain. J. Biol. Chem. 2002, 277:39696-39702.
42. Kim J.O., et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J. Korean Med. Sci. 2007, 22(Suppl.):S38-S46.
43. Cabral H.R. The tumoricidal effect of Trypanosoma cruzi: its intracellular cycle and the immune response of the host. Med. Hypotheses 2000, 54:1-6.
44. Hauschka T.S., Goodwin M.B. Trypanosoma cruzi Endotoxin (KR) in the Treatment of Malignant Mouse Tumors. Science 1948, 107:600-602.
45. Auerbach R., et al. Angiogenesis assays: a critical overview. Clin. Chem. 2003, 49:32-40.
46. Lopez N.C., et al. Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin. PLoS Negl. Trop. Dis. 2010, 4:e730.
47. Coppolino M.G., et al. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997, 386:843-847.
48. Coppolino M.G., Dedhar S. Ligand-specific, transient interaction between integrins and calreticulin during cell adhesion to extracellular matrix proteins is dependent upon phosphorylation/dephosphorylation events. Biochem. J. 1999, 340(Pt 1):41-50.
49. Vucenik I., et al. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 2004, 25:2115-2123.
50. Sheu S.J., et al. Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin. Exp. Eye Res. 2005, 81:673-679.
51. Li L., et al. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice. Gut 2006, 55:259-265.
52. Berwin B., et al. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J. Biol. Chem. 2004, 279:51250-51257.
53. Berwin B., et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 2003, 22:6127-6136.
54. Radsak M.P., et al. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 2003, 101:2810-2815.
55. Adachi H., et al. Expression cloning of a novel scavenger receptor from human endothelial cells. J. Biol. Chem. 1997, 272:31217-31220.
56. Molina M.C., et al. An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol. Biochem. Parasitol. 2005, 140:133-140.
57. Bohlson S.S., et al. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol. Immunol. 2007, 44:33-43.
58. Ricklin D., et al. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
59. Arlaud G.J., et al. Structural biology of C1. Biochem. Soc. Trans. 2002, 30(Pt 6):1001-1006.
60. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 2004, 41:1089-1098.
61. Michalak M., et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J. 2009, 417:651-666.
62. Tesniere A., et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 2008, 20:504-511.
63. Gold L.I., et al. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. J. Invest. Dermatol. Symp. Proc. 2006, 11:57-65.
64. Nanney L.B., et al. Calreticulin enhances porcine wound repair by diverse biological effects. Am. J. Pathol. 2008, 173:610-630.
65. Holaska J.M., et al. Calreticulin is a receptor for nuclear export. J. Cell Biol. 2001, 152:127-140.
66. Burns K., et al. Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 1994, 367:476-480.
67. Dedhar S., et al. Inhibition of nuclear hormone receptor activity by calreticulin. Nature 1994, 367:480-483.
68. Nickenig G., et al. Destabilization of AT(1) receptor mRNA by calreticulin. Circ. Res. 2002, 90:53-58.
69. Singh N.K., et al. Identification of calreticulin as a rubella virus RNA binding protein. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:12770-12774.
70. Timchenko L.T., et al. Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol. Cell Biol. 2002, 22:7242-7257.
71. Iakova P., et al. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. EMBO J. 2004, 23:406-417.
72. Totary-Jain H., et al. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circ. Res. 2005, 97:1001-1008.
73. Labriola C.A., et al. Endoplasmic reticulum calcium regulates the retrotranslocation of Trypanosoma cruzi calreticulin to the cytosol. PLoS One 2010, 5.
74. Johnson S., et al. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001, 11:122-129.
75. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br. J. Haematol. 2005, 128:303-309.
76. Gupta K., Zhang J. Angiogenesis: a curse or cure?. Postgrad. Med. J. 2005, 81:236-242.
77. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
78. Toledo V., et al. Comparative antiangiogenic effects of Trypanosoma cruzi and Homo sapiens sapiens calreticulins. Biol. Res. 2010, 43:287-289.